ANI Pharmaceuticals, Inc. (ANIP) Revenue History
Annual and quarterly revenue from 1998 to present
ANIP Revenue Over Time (1998–2025)
ANIP Revenue Growth History
20 of 25 years with positive growth- FY1998 revenue growth
- N/A
- FY1999 revenue growth
- -100.0%
- FY2000 revenue growth
- N/A
- FY2001 revenue growth
- N/A
- FY2002 revenue growth
- +62.2%
- FY2003 revenue growth
- -97.7%
- FY2004 revenue growth
- +18.9%
- FY2005 revenue growth
- +231.7%
- FY2006 revenue growth
- +5488.8%
- FY2007 revenue growth
- -96.6%
- FY2008 revenue growth
- +666.8%
- FY2009 revenue growth
- -66.7%
- FY2010 revenue growth
- +96.7%
- FY2011 revenue growth
- -82.4%
- FY2012 revenue growth
- +428.7%
- FY2013 revenue growth
- +1207.5%
- FY2014 revenue growth
- +86.1%
- FY2015 revenue growth
- +36.4%
- FY2016 revenue growth
- +68.5%
- FY2017 revenue growth
- +37.5%
- FY2018 revenue growth
- +14.0%
- FY2019 revenue growth
- +2.5%
- FY2020 revenue growth
- +0.9%
- FY2021 revenue growth
- +3.7%
- FY2022 revenue growth
- +46.4%
- FY2023 revenue growth
- +53.9%
- FY2024 revenue growth
- +26.2%
- FY2025 revenue growth
- +43.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $237.5M | +20.5% |
| Q4 2025 | $247.1M | +29.6% |
| Q3 2025 | $227.8M | +53.6% |
| Q2 2025 | $211.4M | +53.1% |
| Q1 2025 | $197.1M | +43.4% |
| Q4 2024 | $190.6M | +44.8% |
| Q3 2024 | $148.3M | +12.5% |
| Q2 2024 | $138.0M | +18.4% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ANIP's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ANIP Revenue Analysis (1998–2025)
Current Revenue & Growth
As of June 22, 2026, ANI Pharmaceuticals, Inc. (ANIP) generated trailing twelve-month (TTM) revenue of $923.7 million, reflecting exceptional growth of +20.5% year-over-year. The most recent quarter (Q1 2026) recorded $237.5 million in revenue, down 3.9% sequentially.
Historical Growth Trajectory
ANIP's 5-year compound annual growth rate (CAGR) stands at +33.5%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +40.8% exceeds the 5-year average, indicating an acceleration in the most recent period. ANI Pharmaceuticals, Inc.'s highest annual revenue of $883.4 million was recorded in 2025, an all-time high.
Revenue by Segment
ANIP's revenue is primarily driven by Sales of rare disease pharmaceutical products (48%), Total Sales of Generics and Other (45%), and Sales of Established Brands (7%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including AMRX (+8.0% YoY), LNTH (+0.6% YoY), and PRGO (-3.6% YoY) — ANIP has outperformed the peer group in revenue growth. Compare ANIP vs AMRX →
ANIP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ANIPCurrent | $924M | +20.5% | +33.5% | 9.2% | |
 AMRX | $3.0B | +8.0% | +8.7% | -0.2% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% |
ANIP Historical Revenue Data (1998–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $883.4M | +43.8% | $450.6M | 51.0% | $81.2M | 9.2% |
| 2024 | $614.4M | +26.2% | $364.2M | 59.3% | $584K | 0.1% |
| 2023 | $486.8M | +53.9% | $305.3M | 62.7% | $47.0M | 9.6% |
| 2022 | $316.4M | +46.4% | $177.6M | 56.1% | $-35,283,000 | -11.2% |
| 2021 | $216.1M | +3.7% | $115.5M | 53.5% | $-39,793,000 | -18.4% |
| 2020 | $208.5M | +0.9% | $121.3M | 58.2% | $-16,016,000 | -7.7% |
| 2019 | $206.5M | +2.5% | $143.4M | 69.4% | $16.4M | 7.9% |
| 2018 | $201.6M | +14.0% | $128.6M | 63.8% | $35.4M | 17.5% |
| 2017 | $176.8M | +37.5% | $97.8M | 55.3% | $28.3M | 16.0% |
| 2016 | $128.6M | +68.5% | $79.8M | 62.1% | $20.1M | 15.6% |
| 2015 | $76.3M | +36.4% | $63.6M | 83.4% | $32.7M | 42.8% |
| 2014 | $56.0M | +86.1% | $44.5M | 79.5% | $20.0M | 35.7% |
| 2013 | $30.1M | +1207.5% | $20.1M | 66.8% | $898K | 3.0% |
| 2012 | $2.3M | +428.7% | $-6,866,264 | -298.4% | $-23,171,582 | -1007.1% |
| 2011 | $435K | -82.4% | $385K | 88.5% | $-50,926,830 | -11703.0% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ANIP — Frequently Asked Questions
Quick answers to the most common questions about buying ANIP stock.
Is ANIP's revenue growth accelerating or slowing?
ANIP revenue growth is accelerating. TTM revenue reached $924M, up +20.5% year-over-year — ahead of the 5-year CAGR of +33.5%. This indicates the business is expanding faster than its historical baseline.
What is ANIP's revenue history from 1998 to 2026?
ANI Pharmaceuticals, Inc. (ANIP) revenue history spans 1998 to 2026. TTM revenue as of 2026 is $924M, growing at +20.5% YoY. The 5-year CAGR is +33.5%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ANIP's long-term revenue growth rate (CAGR)?
ANI Pharmaceuticals, Inc.'s 5-year revenue CAGR of +33.5% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +20.5% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ANIP.
Why does ANIP's quarterly revenue fluctuate?
ANIP quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. ANI Pharmaceuticals, Inc.'s revenue data from 1998 to 2026 shows full historical quarterly detail on this page.
How is ANIP's revenue distributed by segment?
ANIP reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ANIP's revenue compare to industry peers?
ANI Pharmaceuticals, Inc. (ANIP) with TTM revenue of $924M and +20.5% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.